A mAb for the detection of the antiretroviral drug emtricitabine

Antibody-based testing for emtricitabine (FTC), a critical component of pre-exposure prophylaxis and antiretroviral therapy, would provide low-cost detection for clinical monitoring to improve adherence. We developed a mAb (5D2) to FTC and demonstrated its high specificity and physiologically releva...

Descripción completa

Detalles Bibliográficos
Autores principales: Youngpairoj, Ae S., Vanderford, Thomas H., Reed, Matthew S., Granade, Timothy C., Pau, Chou-Pong, Pohl, Jan, Switzer, William M., Heneine, Walid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594139/
https://www.ncbi.nlm.nih.gov/pubmed/36111696
http://dx.doi.org/10.1097/QAD.0000000000003357
Descripción
Sumario:Antibody-based testing for emtricitabine (FTC), a critical component of pre-exposure prophylaxis and antiretroviral therapy, would provide low-cost detection for clinical monitoring to improve adherence. We developed a mAb (5D2) to FTC and demonstrated its high specificity and physiologically relevant linear range of detection in a competitive enzyme immunoassay. Thus, this mAb is a key reagent that will enable simple and low-cost lateral flow assays and enzyme immunoassays for adherence monitoring.

Ejemplares similares